An observational study in Sickle Cell Disease (SCD), sponsored by Ain Shams University. Recruiting at 2 sites in Egypt. Open to participants aged Up to 39 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Ain Shams University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Anemia, Sickle Cell with a site in Egypt — 9 open to participants now, 10 under way, 3 of them phase 3. Anemia, Sickle Cell · Egypt.
Among the 33 studies in Anemia, Sickle Cell with a site in Egypt, this one is one of 3 that started in 2024, is one of 4 observational ones, and was the 31st registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →9 of the 33 studies in Anemia, Sickle Cell with a site in Egypt are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Egypt, United States, Canada and 14 more countries
Ages 2+
Cairo University · Sites in Egypt
Ages 20–50
Adly A Adam · Sites in Egypt
Ages 9–14 · Healthy volunteers
Sohag University · Sites in Egypt
Ages 1–18 · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 2–30
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: Up to 39 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 13 · Phase 4 4
First in 2011; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 100 across 296 observational studies indexed under Anemia, Sickle Cell.
Median enrollment 91 across the 29 interventional studies, 53 across the 4 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 33 have an industry lead sponsor. The 10 most frequent:
Ain Shams University is the lead sponsor of 1,956 studies on the registry; 431 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ain Shams University has 6 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
2 of the studies in Anemia, Sickle Cell with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07800247Ain Shams UniversityHemoglobin Disorders in Egypt: Sickle Cell Disease Ain Shams University Institutional Registry | 2027-01-01 |
| NCT07200869Assiut UniversityOutcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Anemia, Sickle Cell with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a retrospective descriptive study to create an institutional registry that will continue as a prospective follow-up non-intervention study that will be carried out at Hematology Oncology and BMT Department, Children's Hospital, Ain-Shams University, Cairo, Egypt.
children, adolescents and young adults with sickle cell disease who were following at Hematology Oncology and BMT Unit, Children's Hospital, Ain Shams University from the initiation of clinic in 1975 till 01 Jan 2027.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
We will start with those who were/are following at Hematology Oncology and BMT Unit, Children's Hospital, Ain Shams University
Institutional database
To create databases and institutional registry for managing the clinical data
Time frame: 2 years
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Jan 2027, 33 months after the start.
Of 130 non-industry observational studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 109. This study's planned 33 months is below that.
Counting every sponsor, half of 139 studies reached it within 49 months; a quarter within 24 and three quarters within 109.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.